Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | BLM | P54132 | 2/20 | 0.68 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | MPO | P05164 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.68 |
| ▸ | APAF1 | O14727 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 3/20 | 0.52 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.52 |
| ▸ | HTR7 | P34969 | 2/20 | 0.52 |
| ▸ | HTR2B | P41595 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tryptophan SCHEMBL3495872 | 0.93 | KDM4E (0.59) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL4261643 | 0.93 | KDM4E (0.67) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL1487570 | 0.92 | KMT2A (0.80) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL6146838 | 0.92 | KMT2A (0.80) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL4852909 | 0.91 | KDM4E (0.82) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL4852913 | 0.91 | KDM4E (0.82) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL11880165 | 0.91 | KDM4E (0.82) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL8814131 | 0.91 | KDM4E (0.82) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL10527499 | 0.91 | KDM4E (0.82) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL3495876 | 0.91 | KDM4E (0.67) | KDM4EMAPTKMT2ALMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100143364-A1 | Chimeric Antibodies, Compositions and Methods for Treating Cocaine-Related Disorders | VYBION, INC. (US) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143364-A1 | Chimeric Antibodies, Compositions and Methods for Treating Cocaine-Related Disorders | CES2, CHRNA5, CHRNA3 | KDM4E 1096/4885MAPT 61/4885KMT2A 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.